TIXiMED Receives FDA Clearance for Phase 1 Trial of Oral Type 1 Diabetes Drug, TIX100

• TIXiMED Inc., a UAB startup, has received FDA clearance to begin clinical trials for TIX100, a novel oral drug for Type 1 diabetes.
• TIX100's development stems from decades of research by Dr. Anath Shalev at UAB, aiming to ease the burden of insulin injections for T1D patients.
• The oral availability of TIX100 represents a potential breakthrough in T1D treatment, offering a more convenient alternative to existing therapies.
• This Phase 1 trial marks a significant step toward translating diabetes research into an improved treatment option for individuals with Type 1 diabetes.

The University of Alabama at Birmingham (UAB) startup, TIXiMED Inc., has been granted FDA clearance to proceed with clinical trials for its innovative oral Type 1 diabetes drug, TIX100. This clearance signifies a pivotal advancement in T1D treatment, paving the way for human studies to commence.

The foundation of TIX100 lies in extensive research conducted over decades by Dr. Anath Shalev, the Nancy R. and Eugene C. Gwaltney Family Endowed Chair in Juvenile Diabetes Research at UAB's Division of Endocrinology, Diabetes and Metabolism, and the Director of the UAB Comprehensive Diabetes Center.

Potential Impact of Oral TIX100

Dr. Shalev emphasized the potential benefits of TIX100's oral availability, stating, "Since TIX100 is available orally, it promises to ease the burden of the multiple daily insulin injections or insulin infusions people with T1D depend on." She further expressed enthusiasm about the translation of their research into a more effective diabetes treatment, potentially offering a breakthrough for individuals with T1D.

The commencement of clinical trials represents a critical stage in evaluating the safety and efficacy of TIX100 in humans, with the ultimate goal of providing an improved therapeutic option for managing Type 1 diabetes.